Table 2:
Characteristics of the three cohorts as defined by presence/absence of CRVI by day 180.
| CRV Infection by day 180 | No CRV infection | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Variable | HaploCy N(%) N = 117 |
SibCy N(%) N = 65 |
SibCNI N(%) N = 151 |
HaploCy N(%) N = 640 |
SibCy N(%) N = 338 |
SibCNI N(%) N = 1454 |
| Number of centers | 46 | 34 | 56 | 97 | 72 | 99 |
|
| ||||||
|
Patient Related
| ||||||
| Gender, Male | 77 (66) | 39 (60) | 79 (52) | 382 (60) | 204 (60) | 854 (59) |
|
| ||||||
| Age at transplant, years | ||||||
| ≤10 | 8 ( 7) | 1 ( 2) | 11 ( 7) | 27 ( 4) | 3 (<1) | 30 ( 2) |
| 11–20 | 12 (10) | 4 ( 6) | 4 ( 3) | 39 ( 6) | 19 ( 6) | 81 ( 6) |
| 21–30 | 12 (10) | 16 (25) | 13 ( 9) | 56 ( 9) | 53 (16) | 102 ( 7) |
| 31–40 | 5 ( 4) | 10 (15) | 8 ( 5) | 39 ( 6) | 52 (15) | 129 ( 9) |
| 41–50 | 17 (15) | 9 (14) | 22 (15) | 54 ( 8) | 58 (17) | 183 (13) |
| 51–60 | 25 (21) | 11 (17) | 35 (23) | 127 (20) | 71 (21) | 357 (25) |
| 61–70 | 29 (25) | 12 (18) | 51 (34) | 226 (35) | 73 (22) | 498 (34) |
| >70 | 9 ( 8) | 2 ( 3) | 7 ( 5) | 72 (11) | 9 ( 3) | 74 ( 5) |
|
| ||||||
| Karnofsky/Lansky performance status | ||||||
| ≥90 | 64 (55) | 37 (57) | 91 (60) | 326 (51) | 196 (58) | 855 (59) |
| 80–89 | 34 (29) | 18 (28) | 45 (30) | 195 (30) | 84 (25) | 404 (28) |
| <80 | 16 (14) | 10 (15) | 15 (10) | 103 (16) | 55 (16) | 185 (13) |
| Missing | 3 ( 3) | 0 | 0 | 16 ( 3) | 3 (<1) | 10 (<1) |
|
| ||||||
| HCT-CI | ||||||
| 0 | 32 (27) | 10 (15) | 37 (25) | 167 (26) | 93 (28) | 355 (24) |
| 1–2 | 29 (25) | 17 (26) | 40 (26) | 180 (28) | 107 (32) | 407 (28) |
| 3–4 | 38 (32) | 18 (28) | 48 (32) | 173 (27) | 86 (25) | 428 (29) |
| 5+ | 18 (15) | 20 (31) | 26 (17) | 119 (19) | 51 (15) | 259 (18) |
| Missing | 0 | 0 | 0 | 1 (<1) | 1 (<1) | 5 (<1) |
|
| ||||||
|
Donor Related
| ||||||
| Donor/recipient gender match | ||||||
| Male-Male | 49 (42) | 24 (37) | 47 (31) | 240 (38) | 132 (39) | 460 (32) |
| Male-Female | 21 (18) | 19 (29) | 32 (21) | 159 (25) | 80 (24) | 315 (22) |
| Female-Male | 28 (24) | 15 (23) | 32 (21) | 142 (22) | 72 (21) | 394 (27) |
| Female-Female | 19 (16) | 7 (11) | 40 (26) | 99 (15) | 54 (16) | 284 (20) |
| Missing | 0 | 0 | 0 | 0 | 0 | 1 (<1) |
|
| ||||||
|
Disease Related
| ||||||
| Disease | ||||||
| AML | 87 (74) | 53 (82) | 105 (70) | 441 (69) | 257 (76) | 920 (63) |
| ALL | 5 ( 4) | 2 ( 3) | 7 ( 5) | 21 ( 3) | 17 ( 5) | 53 ( 4) |
| MDS | 25 (21) | 10 (15) | 39 (26) | 178 (28) | 64 (19) | 481 (33) |
|
| ||||||
| Disease status | ||||||
| AML/ALL, early | 49 (42) | 31 (48) | 59 (39) | 259 (40) | 158 (47) | 660 (45) |
| AML/ALL, intermediate | 27 (23) | 11 (17) | 27 (18) | 116 (18) | 66 (20) | 183 (13) |
| AML/ALL, advanced | 15 (13) | 13 (20) | 22 (15) | 82 (13) | 48 (14) | 122 ( 8) |
| AML/ALL, unknown | 1 (<1) | 0 | 5 ( 3) | 5 (<1) | 2 (<1) | 10 (<1) |
| MDS, early | 12 (10) | 3 ( 5) | 10 ( 7) | 64 (10) | 21 ( 6) | 169 (12) |
| MDS, advanced | 13 (11) | 7 (11) | 28 (19) | 114 (18) | 43 (13) | 310 (21) |
|
| ||||||
| Cytogenetics for AML/ALL | ||||||
| Normal | 10 ( 9) | 3 ( 5) | 7 ( 5) | 32 ( 5) | 25 ( 7) | 76 ( 5) |
| Favorable | 3 ( 3) | 2 ( 3) | 2 ( 1) | 20 ( 3) | 16 ( 5) | 37 ( 3) |
| Intermediate | 36 (31) | 20 (31) | 54 (36) | 220 (34) | 120 (36) | 464 (32) |
| Poor | 42 (36) | 28 (43) | 40 (26) | 161 (25) | 104 (31) | 334 (23) |
| Other | 1 (<1) | 1 ( 2) | 7 ( 5) | 19 ( 3) | 5 ( 1) | 42 ( 3) |
| Not tested/Missing | 0 | 1 ( 2) | 2 ( 1) | 10 ( 2) | 4 ( 1) | 20 ( 1) |
| MDS N/A | 25 (21) | 10 (15) | 39 (26) | 178 (28) | 64 (19) | 481 (33) |
|
| ||||||
| IPSS-R prior to transplant (MDS only) | ||||||
| Very low | 1 (<1) | 3 ( 5) | 1 (<1) | 18 ( 3) | 11 ( 3) | 59 ( 4) |
| Low | 9 ( 8) | 4 ( 6) | 11 ( 7) | 58 ( 9) | 18 ( 5) | 122 ( 8) |
| Intermediate | 8 ( 7) | 3 ( 5) | 13 ( 9) | 45 ( 7) | 19 ( 6) | 147 (10) |
| High | 6 ( 5) | 0 | 7 ( 5) | 24 ( 4) | 10 ( 3) | 66 ( 5) |
| Very high | 0 | 0 | 4 ( 3) | 13 ( 2) | 3 (<1) | 34 ( 2) |
| Missing | 1 (<1) | 0 | 3 ( 2) | 20 ( 3) | 3 (<1) | 53 ( 4) |
| AML/ALL N/A | 92 (79) | 55 (85) | 112 (74) | 462 (72) | 274 (81) | 973 (67) |
|
| ||||||
|
Transplant Related
| ||||||
| Graft type | ||||||
| Bone Marrow | 51 (44) | 24 (37) | 22 (15) | 257 (40) | 107 (32) | 178 (12) |
| Peripheral blood | 66 (56) | 41 (63) | 129 (85) | 383 (60) | 231 (68) | 1276 (88) |
|
| ||||||
| Conditioning regimen intensity | ||||||
| Myeloablative | 53 (45) | 38 (58) | 89 (59) | 261 (41) | 184 (54) | 846 (58) |
| RIC/NMA | 64 (55) | 27 (42) | 62 (41) | 379 (59) | 154 (46) | 608 (42) |
|
| ||||||
| TBI, yes | 78 (67) | 40 (62) | 48 (32) | 453 (71) | 194 (57) | 388 (27) |
|
| ||||||
| Time from diagnosis to transplant | ||||||
| <6 month | 49 (42) | 33 (51) | 81 (54) | 266 (42) | 147 (43) | 809 (56) |
| 6 month-12 months | 30 (26) | 17 (26) | 30 (20) | 165 (26) | 100 (30) | 318 (22) |
| >12 months | 38 (32) | 15 (23) | 39 (26) | 208 (32) | 90 (27) | 324 (22) |
| Missing | 0 | 0 | 1 (<1) | 1 (<1) | 1 (<1) | 3 (<1) |
|
| ||||||
| Year of transplant | ||||||
| 2012 – 2014 | 24 (21) | 13 (20) | 101 (68) | 146 (23) | 74 (22) | 718 (49) |
| 2015 – 2017 | 93 (79) | 52 (80) | 63 (42) | 494 (67) | 264 (68) | 736 (51) |